Li Kang Biomedical Co Ltd (TWO:6242) — Market Cap & Net Worth
Market Cap & Net Worth: Li Kang Biomedical Co Ltd (6242)
Li Kang Biomedical Co Ltd (TWO:6242) has a market capitalization of $38.53 Million (NT$1.22 Billion) as of May 3, 2026. Listed on the TWO stock exchange, this Taiwan-based company holds position #22817 globally and #1431 in its home market, demonstrating a 0.92% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Li Kang Biomedical Co Ltd's stock price NT$38.45 by its total outstanding shares 31807000 (31.81 Million). Analyse 6242 cash flow metrics to see how efficiently the company converts income to cash.
Li Kang Biomedical Co Ltd Market Cap History: 2015 to 2026
Li Kang Biomedical Co Ltd's market capitalization history from 2015 to 2026. Data shows growth from $23.23 Million to $38.53 Million (3.88% CAGR).
Li Kang Biomedical Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Li Kang Biomedical Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.08x
Li Kang Biomedical Co Ltd's market cap is 0.08 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.56x
Li Kang Biomedical Co Ltd's market cap is 0.56 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $23.23 Million | $455.81 Million | $52.85 Million | 0.05x | 0.44x |
| 2016 | $26.82 Million | $450.61 Million | $61.51 Million | 0.06x | 0.44x |
| 2017 | $35.84 Million | $495.94 Million | $133.74 Million | 0.07x | 0.27x |
| 2018 | $26.27 Million | $495.57 Million | $76.74 Million | 0.05x | 0.34x |
| 2019 | $25.72 Million | $483.30 Million | $72.02 Million | 0.05x | 0.36x |
| 2020 | $24.97 Million | $456.72 Million | $69.27 Million | 0.05x | 0.36x |
| 2021 | $28.22 Million | $386.97 Million | $51.44 Million | 0.07x | 0.55x |
| 2022 | $43.92 Million | $684.25 Million | $112.09 Million | 0.06x | 0.39x |
| 2023 | $55.61 Million | $629.38 Million | $110.99 Million | 0.09x | 0.50x |
| 2024 | $42.99 Million | $565.51 Million | $77.02 Million | 0.08x | 0.56x |
Competitor Companies of 6242 by Market Capitalization
Companies near Li Kang Biomedical Co Ltd in the global market cap rankings as of May 3, 2026.
Key companies related to Li Kang Biomedical Co Ltd by market ranking:
- Booking Holdings Inc (NASDAQ:BKNG): Ranked #166 globally with a market cap of $134.32 Billion USD.
- Royal Caribbean Cruises Ltd (NYSE:RCL): Ranked #372 globally with a market cap of $72.42 Billion USD.
- Airbnb Inc (NASDAQ:ABNB): Ranked #437 globally with a market cap of $60.00 Billion USD.
- Trip.com Group Ltd ADR (NASDAQ:TCOM): Ranked #765 globally with a market cap of $34.61 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #166 | Booking Holdings Inc | NASDAQ:BKNG | $134.32 Billion | $169.63 |
| #372 | Royal Caribbean Cruises Ltd | NYSE:RCL | $72.42 Billion | $265.55 |
| #437 | Airbnb Inc | NASDAQ:ABNB | $60.00 Billion | $141.66 |
| #765 | Trip.com Group Ltd ADR | NASDAQ:TCOM | $34.61 Billion | $52.95 |
Li Kang Biomedical Co Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Li Kang Biomedical Co Ltd's market cap moved from $23.23 Million to $ 38.53 Million, with a yearly change of 3.88%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | NT$38.53 Million | -2.04% |
| 2025 | NT$39.33 Million | -8.51% |
| 2024 | NT$42.99 Million | -22.70% |
| 2023 | NT$55.61 Million | +26.62% |
| 2022 | NT$43.92 Million | +55.66% |
| 2021 | NT$28.22 Million | +13.02% |
| 2020 | NT$24.97 Million | -2.93% |
| 2019 | NT$25.72 Million | -2.08% |
| 2018 | NT$26.27 Million | -26.71% |
| 2017 | NT$35.84 Million | +33.62% |
| 2016 | NT$26.82 Million | +15.48% |
| 2015 | NT$23.23 Million | -- |
End of Day Market Cap According to Different Sources
On May 3rd, 2026 the market cap of Li Kang Biomedical Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $38.53 Million USD |
| MoneyControl | $38.53 Million USD |
| MarketWatch | $38.53 Million USD |
| marketcap.company | $38.53 Million USD |
| Reuters | $38.53 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Li Kang Biomedical Co Ltd
Li Kang Biomedical Co., Ltd. manufactures and sells supplement, cosmeceutical, and hygienic drink products. It also engages in the management and consulting of tourism factory business; and offers telemarketing services. The company was formerly known as BAFO Technologies Corporation and changed its name to Li Kang Biomedical Co., Ltd. in September 2014. Li Kang Biomedical Co., Ltd. was founded i… Read more